2021年欧洲泌尿外科学会指南更新:转移性尿路上皮癌
欧洲泌尿外科学会指南小组每年对转移性尿路上皮癌进行范围综述并更新指南。推荐以铂类为基础的化疗作为适合顺铂或卡铂患者的一线标准治疗,PD-L1阳性且不适合顺铂者可接受免疫治疗,铂类化疗后无进展者可予阿维鲁单抗维持治疗,无维持治疗者二线推荐帕博利珠单抗,后线治疗中恩诺单抗维多汀改善总生存,厄达替尼对FGFR3改变有活性。
要点
- 推荐以铂类为基础的化疗作为适合顺铂或卡铂患者的一线标准治疗。
- PD-L1阳性且不适合顺铂者可接受阿替利珠单抗或帕博利珠单抗免疫治疗。
- 铂类化疗后无进展者推荐阿维鲁单抗维持治疗;无维持治疗者二线推荐帕博利珠单抗。
核心结论
- 2021年EAU指南更新为转移性尿路上皮癌的治疗提供了详细和当代的信息,以供融入临床实践。
研究设计与样本
- 指南小组每年对转移性尿路上皮癌主题进行全面范围综述,检索Medline、EMBASE和Cochrane图书馆,形成年度指南更新。
主要发现
- 以铂类为基础的化疗是推荐的一线标准治疗,适用于所有适合接受顺铂或卡铂的患者。
- PD-L1阳性且不适合顺铂的患者可接受免疫治疗(阿替利珠单抗或帕博利珠单抗)。
- 铂类化疗后无进展者推荐后续维持免疫治疗(阿维鲁单抗)。
- 无维持治疗者,推荐的二线方案为免疫治疗(帕博利珠单抗)。
- 后线治疗中,抗体药物偶联物恩诺单抗维多汀显示总生存改善,FGFR抑制剂厄达替尼在FGFR3改变时似乎有活性。
关键数值与推荐
- 推荐以铂类为基础的化疗作为适合顺铂或卡铂患者的一线标准治疗。
- PD-L1阳性且不适合顺铂者可接受阿替利珠单抗或帕博利珠单抗免疫治疗。
- 铂类化疗后无进展者推荐阿维鲁单抗维持免疫治疗。
- 无维持治疗者二线推荐帕博利珠单抗免疫治疗。
- 后线治疗中恩诺单抗维多汀改善总生存,厄达替尼在FGFR3改变时似乎有活性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Treatment of metastatic urothelial carcinoma is currently undergoing a rapid evolution. OBJECTIVE: This overview presents the updated European Association of Urology (EAU) guidelines for metastatic urothelial carcinoma. EVIDENCE ACQUISITION: A comprehensive scoping exercise covering the topic of metastatic urothelial carcinoma is performed annually by the Guidelines Panel. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries, resulting in yearly guideline updates. EVIDENCE SYNTHESIS: Platinum-based chemotherapy is the recommended first-line standard therapy for all patients fit to receive either cisplatin or carboplatin. Patients positive for programmed death ligand 1 (PD-L1) and ineligible for cisplatin may receive immunotherapy (atezolizumab or pembrolizumab). In case of nonprogressive disease on platinum-based chemotherapy, subsequent maintenance immunotherapy (avelumab) is recommended. For patients without maintenance therapy, the recommended second-line regimen is immunotherapy (pembrolizumab). Later-line treatment has undergone recent advances: the antibody-drug conjugate enfortumab vedotin demonstrated improved overall survival and the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib appears active in case of FGFR3 alterations. CONCLUSIONS: This 2021 update of the EAU guideline provides detailed and contemporary information on the treatment of metastatic urothelial carcinoma for incorporation into clinical practice. PATIENT SUMMARY: In recent years, several new treatment options have been introduced for patients with metastatic urothelial cancer (including bladder cancer and cancer of the upper urinary tract and urethra). These include immunotherapy and targeted treatments. This updated guideline informs clinicians and patients about optimal tailoring of treatment of affected patients.
引用
- Cathomas R, Lorch A, Bruins HM, et al. The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. Eur Urol. 2021. PMID: 34742583. doi:10.1016/j.eururo.2021.09.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。